Item 5. Other Information

During the quarter ended September 30, 2023, none of our officers or directors adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K., except as follows:

• On August 11, 2023, George Massaro, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement for the sale of up to 332 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is May 15, 2024.

• On August 16, 2023, Victoria Creamer, our Corporate Executive Vice President and Chief People Officer, adopted a Rule 10b5-1 trading agreement for the sale of up to 5,526 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is February 22, 2024.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.